granisetron

(redirected from Sancuso)

granisetron

 [gră-nis´ĕ-tron]
an antiemetic used in conjunction with cancer chemotherapy or radiotherapy; administered orally or intravenously as the hydrochloride salt.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

granisetron

Kytril® Oncology A 5-HT3–serotonin receptor antagonist antiemetic used for Pts receiving chemotherapy–eg, cisplatin, cyclophosphamide Adverse effects Headache–35%, constipation–30%, asthenia, somnolence, diarrhea
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

Granisetron

A serotonin antagonist drug that blocks the nausea receptors in the small intestine and is used to control sickness and vomiting after surgery and in patients on anticancer chemotherapy. It can be used in children. A brand name is Kytril.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
In July 2018, Sancuso (Granisetron Transdermal System), which the Group obtained its exclusive license rights for commercialisation and promotion in China (excluding Beijing, Shanghai and Guangzhou), has been approved for launch by the NMPA.
It was reported on Friday that the contract has been signed for commercialisation and promotion of Sancuso (granisetron transdermal delivery system) in the People's Republic of China excluding Taiwan, Hong Kong, Macau and the Retained Territory.
Solasia will retain rights to promote Sancuso in three major cities, including Beijing, Shanghai and Guangzhou, the 'Retained Territory', in the People's Republic of China.
The EMA has granted approval for ProStrakan Group to market SANCUSO (Granisetron Transdermal System) in the EU, with 3M Drug Delivery Systems as the manufacturer.
"SANCUSO is a great illustration of the patient-friendly benefits of transdermal treatment," said Jim Ingebrand, president and general manager, 3M Drug Delivery Systems.
ProStraken, based in Galashiels in the Borders, have developed Sancuso, a drug for chemotherapy patients which eases symptoms of nausea and vomiting.
He added: "The launch will make Sancuso available for the first time to prevent nausea and vomiting in chemotherapy patients.
Subsequent approval by the US Food and Drug Administration (FDA), ProStrakan plans to market Rapinyl alongside its other oncology support product, Sancuso for the prevention of chemotherapy-induced nausea & vomiting (CINV), which is currently under consideration for approval by the FDA.
3 March 2010 - Japanese life science company Solasia Pharma KK announced today it granted Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (Sancuso) in Taiwan, Hong Kong, Singapore and Malaysia.
According to Solasia, Sancuso is the first and only commercialised extended release granisetron transdermal product.
M2 EQUITYBITES-3 March 2010-Solasia Pharma and Kyowa Hakko Kirin sign licence agreement forA Sancuso in Asia(C)2010 M2 COMMUNICATIONS http://www.m2.com
PROSTRAKAN, a Borders pharmaceutical group, have signed a distribution agreement in South Korea with LG Life Sciences for Sancuso, a patch to prevent chemotherapy-induced nausea and vomiting.